Bottom line
A four-component research-peptide combination (GHK-Cu + KPV + BPC-157 + TB-500) representing the GLOW formulation plus KPV, a tripeptide anti-inflammatory fragment of alpha-MSH. The name is a vendor-coined acronym. No published study tests this specific four-component combination.
No established or recommended human dose. Composition (especially GHK-Cu loading) varies markedly by vendor.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| AminoCore Research (2026) | GHK-Cu, KPV, BPC-157, TB-500 | 50 / 10 / 10 / 10 mg (80 mg total) | Vendor-declared |
| Durham Peptides (2026) | GHK-Cu, KPV, BPC-157, TB-500 | 50 / 10 / 10 / 10 mg | Vendor-declared; unverified |
| BergdorfBio (2026) | GHK-Cu, KPV, BPC-157, TB-500 | 25 / 10 / 10 / 10 mg (55 mg total) | Vendor-declared |
| KLOW70 variant | GHK-Cu, KPV, BPC-157 | 50 / 10 / 10 mg (no TB-500) | Vendor-declared |
The KLOW name is not standardised; it is a marketing acronym (KPV, Lysyl=GHK-Cu, Overall repair=BPC, Wound=TB-500). GHK-Cu loading ranges 25–50 mg; some variants omit TB-500.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| GHK-Cu | Endogenous tripeptide; TGF-β upregulation, collagen synthesis, antioxidant | None for four-component blend | No published multi-peptide co-lyophilisation stability study |
| KPV | Tripeptide (Lys-Pro-Val); C-terminal fragment of α-MSH; NF-κB inhibition, anti-inflammatory in colitis models (Dalmasso 2008) | None for this specific blend | PepT1-mediated intestinal uptake; interaction with other components unstudied |
| BPC-157 | Preclinical VEGFR2/NO angiogenesis; GI/tendon repair | None for this specific blend | — |
| TB-500 | Synthetic Tβ4 fragment; actin sequestration; cell migration | None for this specific blend | Identity ambiguity (43 vs 7 AA) |
Combination-specific studies
No published peer-reviewed study tests the GHK-Cu + KPV + BPC-157 + TB-500 four-component combination. The rationale is mechanistic complementarity: four non-overlapping pathways (ECM remodelling, anti-inflammation, angiogenesis, cell migration).
Safety and interaction uncertainties
Four-peptide combination maximises uncertainty: more components = more potential interactions
KPV's NF-κB mechanism may theoretically interfere with the inflammatory phase of repair
Fixed ratio prevents independent dose modulation
No published stability data for the co-lyophilised four-peptide mixture
Molar ratios are massively skewed: tripeptides (GHK-Cu, KPV) dominate by >93% of molar content
Regulatory and product-quality notes
None of the four components is FDA-approved
All are "research use only" products
KPV is sometimes included in cosmetic products as a "peptide complex"
WADA status varies by component; BPC-157 and TB-500 are prohibited
Evidence gaps
No combination-specific study of any kind
No stability or compatibility data for the four-peptide mixture
No dose-ratio optimisation
No human data for any component for the claimed mechanisms
Sources
AminoCore Research. KLOW Blend Analysis. https://aminocoreresearch.com/articles/klow-blend-bpc-157-tb-500-ghk-cu-kpv accessed 2026-08-06.
Durham Peptides. Inside the KLOW Blend. https://www.durhampeptides.ca/post/inside-klow-blend-four-component-breakdown accessed 2026-08-06.
BergdorfBio. KLOW Stack Guide. https://bergdorfbio.com/en/us/guides/klow-stack-leitfaden accessed 2026-08-06.
Your Peptide Brand. KLOW Blend Research Guide. https://yourpeptidebrand.com/klow-blend-research-guide/ accessed 2026-08-06.
Dalmasso G, et al. Am J Physiol Gastrointest Liver Physiol. 2008;295(1):G43-G54. PMID 18436621.